Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S-6472

Known as: S 6472, S6472 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
We conducted a clinical investigation on the use of S6472, an sustained release preparation of cefaclor, in the dermatological… Expand
1986
1986
The S6472 is a 4:6 mixture of 2 types of granules of cefaclor (CCL) coated with different films; one type of granules is soluble… Expand
1986
1986
S6472 is a mixture of cefaclor (CCL) granules with gastric-soluble coating and those with enteric-soluble coating at the ratio… Expand
1985
1985
This study was conducted to develop a prolonged action preparation of cefaclor (CCL) which can offer, with the twice-a-day… Expand
1985
1985
Current (regular) preparation of cefaclor (CCL) require the 3-time-a-day administration. S6472 (sustained release preparation… Expand
1985
1985
To objectively evaluated the usefulness of the standard formulation of cefaclor (CCL) and the long-acting formulation of cefaclor… Expand
1985
1985
A study in which 375 mg of S6472 was orally given to 3 healthy adult volunteers before a meal, after a light meal, and after a… Expand
1985
1985
Fundamental and clinical studies on S6472, a new prolonged acting preparation of cefaclor, were performed and the following… Expand
1985
1985
In order to see absorption and excretion of S6472 (sustained release preparations of cefaclor (CCL], 3 studies regarding, 1… Expand